If You Are a Postmenopausal Woman With Metastatic Breast Cancer of Estrogen-Receptor Positive (ER+) or Unknown Tumor,* Fareston Provides Another Option
Fareston Is a Selective Estrogen-Receptor Modulator (SERM) That:
- Is clinically proven. In a number of important measurements of a drug's effectiveness in treating metastatic ER+ breast cancer in postmenopausal women, Fareston worked just as well as tamoxifen1-4
- May provide the continued benefits of endocrine therapy. Fareston may offer you the continued benefits of endocrine therapy if you cannot tolerate or are otherwise unable to take other endocrine therapies1-6
- Fareston may be an effective alternative for patients who have stopped taking other endocrine therapies because of joint pain1-4,6
- Is available and accessible. Fareston is widely available on commercial and Medicare Part D formularies and is covered by most commercial and Medicare insurance plans.7 In addition, comprehensive support for patients who have been prescribed Fareston can be found through Patient Rx Solutions, including copay savings of up to $150 a month (after paying the first $20) on your out-of-pocket prescription costs**
*"Unknown tumors" are tumors for which the hormonal status (eg, ER+ or ER-) is not known.
References: 1. Fareston [package insert]. Bridgewater, NJ: ProStrakan, Inc; 2012. 2. Gershanovich M, Garin A, Baltina D, et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat. 1997;45(3):251-262. 3. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13(10):2556-2566. 4. Pyrhönen S, Valavaara R, Modig I, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. Br J Cancer. 1997;76(2):270-277. 5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed February 23, 2016. 6. Hong S, Didwania A, Olopade O, et al. The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J Gen Intern Med. 2009;24(suppl 2):S383-S388. 7. Data on file. Bedminster, NJ: Kyowa Kirin, Inc; 2016